Security key
604749101
Mirum Pharmaceuticals, Inc. - Common Stock (MIRM)
CUSIP: 604749101
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 170
- Total 13F value
- $19,902
- Share change
- -90
- SEC-reported price per share
- $117.07
- Number of holders
- 3
- Value change
- -$7,771
- Number of buys
- 3
- Number of sells
- 1
- Shares outstanding
- 60,799,281
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
3
Top holders
3
MIRM full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Mirum Pharmaceuticals, Inc. SEC filings
Mirum Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 604749101
Recent filing periods:
Ownership snapshot
Top reported holders of MIRM - Mirum Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
JANUS HENDERSON GROUP PLC
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
15/15
Latest evidence
31 Mar 2026
13F
13D/G
Lead comparable stake: 12%
13D/G row: JANUS HENDERSON GROUP PLC
Showing 1-6 of 15 holder rows.
Quick read
JANUS HENDERSON GROUP PLC leads the comparable SEC ownership view at 12%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens JANUS HENDERSON GROUP PLC's linked filing trail.
Comparable ownership
Top 5
JANUS HENDERSON GROUP PLC
12%
Frazier Life Sciences IX, L.P.
6.8%
BlackRock, Inc.
5.7%
EVENTIDE ASSET MANAGEMENT, LLC
4.1%
BIOTECHNOLOGY VALUE FUND L P
3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC |
13F
13D/G
Company
|
12%
from 13D/G
|
$641,764,403
6,945,813 shares
|
— | 31 Mar 2026 |
| Frazier Life Sciences IX, L.P. |
13D/G
Patrick J. Heron
|
6.8%
|
$324,522,832
4,108,404 shares
|
+$29,477,804 | 23 Jan 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.7%
from 13D/G
|
$355,342,442
3,846,530 shares
|
— | 31 Mar 2026 |
| EVENTIDE ASSET MANAGEMENT, LLC |
13D/G
13F
Company
|
4.1%
|
$165,372,042
2,093,582 shares
|
-$40,549,990 | 31 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
3%
|
$109,619,710
1,495,290 shares
|
$0 | 30 Sep 2025 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
13%
|
$709,449,208
7,679,684 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
170
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
308
Q2 2026 holders
3
Holder diff
-305
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend